A blood test has been developed that could help target treatment for men with advanced prostate cancer.
Costing less than £50 the test is quick and a relatively cheap way of preventing men from undergoing the side effects of therapy that will fail.
Researchers analysed blood from 265 men with advanced prostate cancer and found those, with multiple copies of a particular gene did not respond to abiraterone and enzalutamide – drugs commonly used to treat advanced cases.
Lead researcher, Dr Gerhardt Attard, from the Centre for Evolution and Cancer at the Institute of Cancer Research in London” said “ “We have developed a robust test that can be used in the clinic to pick out which men with advanced prostate cancer are likely to respond to abiraterone and enzalutamide, and which men might need alternative treatments.”
The test could be a significant step towards moving away from a “one-size-fits-all” approach to treatment.
46,000 men are diagnosed with prostate cancer every year.